Elixir Medical Corporation

Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System

Authors:
Steven Giannos
Date:
Business Wire: May 17, 2017 – MILPITAS, CA, U.S.A. – Elixir Medical Corporation, a developer of products that combine state-ofthe-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE…

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve™ Cx Novolimus Eluting Bioresorbable Coronary Scaffold System

Authors:
Steven Giannos
Date:
Business Wire: November 1, 2016 – SUNNYVALE, CA, U.S.A. – Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent six-month clinical data for the first 25-patient subset of the DESolve™ Cx Clinical…

join_crs.jpg